MedPath

Molecular Signatures of Esophageal Atresia

Not Applicable
Recruiting
Conditions
Esophageal Atresia
Interventions
Procedure: Esophageal biopsy collection during anastomosis
Registration Number
NCT06073158
Lead Sponsor
University Hospital, Lille
Brief Summary

Although several studies have revealed signaling pathways as well as genes potentially involved in the development of esophageal atresia (EA), our understanding of the pathophysiology of EA lags behind improvements in the surgical and clinical care of patients born with this anomaly. However, a causative genetic abnormality can be identified in less than 10% of patients, even using more recent next-generation sequencing techniques. As most cases of EA associated with tracheoesophageal fistula (TOF) are sporadic, and the familial recurrence rate is low (1%), this suggests that epigenetic and environmental factors also contribute to the disease. Further investigations are needed to better understand the mechanisms underlying EA. That information can come from the oesophageal biopsies that are collected in routine care and long-term storage at the hospital. However, the impact of the length of the storage is still unknown.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Anastomosis group :

Born with esophageal atresia Anastomosis performed in Lille hospital Parents consent

  • Control group : Born with esophageal atresia
Exclusion Criteria
  • Both groups :

Parents refusing to participate in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Anastomosis groupEsophageal biopsy collection during anastomosisEsophageal biopsies collected during the anastomosis for the patient with esophageal atresia
Primary Outcome Measures
NameTimeMethod
Comparison of the mRNA expression from esophageal biopsies between long and short term storageThe biopsies will be collected during the first year of life

Transcriptomic profiles will be generated by the identification of mRNA and miRNA expression by 3'RNA-seq and sRNA-seq technologies. Differential expression between long and short term storage will be performed.\[exploratory and untargeted analysis\]

Comparison of the metabolites identification from esophageal biopsies between long and short term storageThe biopsies will be collected during the first year of life

Metabolomic profiles will be generated (untargeted analysis that will include mnulmerous lipids, amino-acids, ...). Differential expression between long and short term storage will be performed. \[exploratory and untargeted analysis\]

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Lille

🇫🇷

Lille, France

© Copyright 2025. All Rights Reserved by MedPath